Addiction

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 2, 2024
Research, Frost, Patent, Partnership, Patient, OUD, G&A, Opioid use disorder, Addiction, GLEN, Consultant, Pharmaceutical industry

GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.

Key Points: 
  • GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
  • Specifically, we conducted meetings and received favorable feedback from both US and European regulators, allowing us to refine our clinical development plan.
  • Cash and cash equivalents were $2.8 million as of December 31, 2023, compared to $4.0 million as of December 31, 2022.
  • Net Loss was $5.1 million for the year ended December 31, 2023, compared to a net loss of $12.7 million for the year ended December 31, 2022.

Virtue Recovery Chandler Launches Comprehensive Program for Long-Term Sobriety

Retrieved on: 
Monday, April 8, 2024
Healing, Physical fitness, Aftercare, Addiction, Hope

CHANDLER, Ariz., April 8, 2024 /PRNewswire-PRWeb/ -- Virtue Recovery Center, a leading name in addiction treatment in Chandler, Arizona, has announced the launch of its groundbreaking program aimed at providing comprehensive support for individuals seeking long-term sobriety. This innovative initiative addresses the multifaceted nature of addiction, offering a path to recovery as personalized as the stories of the individuals it aims to help.

Key Points: 
  • Virtue Recovery Center, a leading name in addiction treatment in Chandler, Arizona, has announced the launch of its groundbreaking program aimed at providing comprehensive support for individuals seeking long-term sobriety.
  • CHANDLER, Ariz., April 8, 2024 /PRNewswire-PRWeb/ -- Virtue Recovery Center, a leading name in addiction treatment in Chandler, Arizona, has announced the launch of its groundbreaking program aimed at providing comprehensive support for individuals seeking long-term sobriety.
  • At the heart of Virtue Recovery Chandler is the conviction that the journey to overcome addiction is as individual as the people who embark on it.
  • The launch of Virtue Recovery's comprehensive program for long-term sobriety marks a significant step forward in the fight against addiction.

TMS Health and Wellness Introduces Cutting-Edge Brain Scanning For Enhanced TMS Therapy Effectiveness

Retrieved on: 
Monday, April 8, 2024
Depression, Mindfulness, Magnetic resonance, Medicine, Health, Neuroimaging, Patient, TMS, Anxiety, Addiction, Chronic pain, Functional, Concierge medicine, Meditation, Wellness, Transcranial magnetic stimulation, Homeopathy, Neurofeedback, Map, Medical imaging

COSTA MESA, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- In a significant advancement for treating anxiety, depression, and other mental health conditions, TMS Health and Wellness proudly announces the integration of comprehensive brain scanning technology into its Transcranial Magnetic Stimulation (TMS) Therapy protocols. This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.

Key Points: 
  • This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.
  • By utilizing detailed brain imaging to map and understand each patient's unique neural patterns, TMS Health and Wellness can customize the application of TMS Therapy with greater precision than ever before.
  • The clinic's expanded services now include:
    With the introduction of brain scanning technology, TMS Health and Wellness reinforces its dedication to pioneering in the mental health space and its mission of treating the "whole person."
  • TMS Therapy enhanced with Full Brain Scans and Functional MRI is available now.

Government of Canada announces support for innovative solutions to address labour challenges in the agriculture and agri-food sector

Retrieved on: 
Friday, April 5, 2024
Automation, ICS, Parliament, Addiction, Mental health, Farmer, Growth, Learning, Social change, Food safety, The Honourable, Controlled-environment agriculture, Human, Plant, Robotics, ISC, Invention, Safety, Food, CEA, SME, Government, Movement

These companies have developed ideas to address challenges such as work productivity, labour shortages, and operational efficiency.

Key Points: 
  • These companies have developed ideas to address challenges such as work productivity, labour shortages, and operational efficiency.
  • -       The Honourable Lawrence MacAulay, Minister of Agriculture and Agri-Food
    "Through the Innovative Solutions Canada program, our government empowers SMEs to drive innovation and solve challenges.
  • Our government supports these efforts through Innovative Solutions Canada, assisting small and medium-sized Canadian businesses in developing new inventions that are crucial for the sector.
  • We are grateful to the Innovative Solutions Canada Program and Agriculture and Agri-Food Canada for their support to develop a market ready solution which we can pioneer in Canada."

Infectious Disease Specialist Calls Campaign against Repurposed Drugs in COVID-19 a ‘Great Hypocrisy’

Retrieved on: 
Thursday, March 21, 2024
Vanderbilt University, COVID, HCQ, Rheumatoid arthritis, Infection, Azithromycin, Lupus, Diabetes, COVID-19, Patient, Knowledge, Journal, Mortality, Addiction, Hydroxychloroquine, AAPS, Dysautonomia, Physician, Ivermectin, IVM, Pharmaceutical industry

Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.

Key Points: 
  • Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.
  • “In fact, all evidence is inherently flawed.”
    Dr. Hoffman points out how inconsistencies and double standards reveal the FDA’s hypocrisy regarding HCQ and ivermectin (IVM).
  • Paxlovid, he writes, has not been shown to be effective in hospitalized COVID patients, whereas the “flawed” study of HCQ demonstrated a greater than 60 percent benefit in reducing mortality.
  • “There is in fact a corpus of knowledge about the use of HCQ, IVM, and other off-label drugs, for example, at c19hcq.org, c19IVM.org18, and earlycovidcare.org,” Dr. Hoffman states.

Impressive $3.3M investment in Basic Mental Health Research

Retrieved on: 
Tuesday, March 19, 2024
Depression, Health, Basics, Mental health, Obesity, Prevalence, Drug discovery, University of Calgary, Insulin, Risk, Knowledge, Insulin resistance, The Honourable, Power Corporation of Canada, Research, Anxiety, University, Laboratory, Health Canada, Woman, Addiction, University of Toronto, Nursing

Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.

Key Points: 
  • Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.
  • The Basics of Better Mental Health Program funds basic research that will provide insight into the causes and onset of mental health conditions, explore the neuropathological changes and information-processing deficits that may eventually lead to new directions for treatments and interventions, and explore the role of sex and gender in mental health.
  • "Brain research plays a critical role in increasing our understanding of the causes and onset of mental health conditions,” says the Honourable Ya’ara Saks, Minister of Mental Health and Addictions.
  • “I am thrilled to support the work being done through the Basics of Better Mental Health Program – this work will support better mental health for all Canadians.”
    “The inclusion of sex-specific biological considerations is instrumental in understanding the biological roots of mental health conditions,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Acadia Healthcare Accelerates Access to Care With Uber Health

Retrieved on: 
Tuesday, April 2, 2024
Physical Therapy, Mental Health, Technology, Managed Care, Law Enforcement, Emergency Services, General Health, Public Policy, Government, Infectious Diseases, Hospitals, Delivery Services, Other Transport, Health, Health Technology, Transport, Apps, Applications, Retail, Other Health, Comprehensive, Opioid, Patient, MAT, Chinese, Addiction, Acadia Healthcare, Senior counsel, CTC, Nursing

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced a collaboration with Uber Health (NYSE:UBER).

Key Points: 
  • Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced a collaboration with Uber Health (NYSE:UBER).
  • The two companies are coming together to improve access to life-saving behavioral health care and addiction treatment by providing patients access to transportation, so they can begin treatment quickly and efficiently.
  • “By joining forces with Uber Health, Acadia Healthcare can quickly and easily connect patients with transportation to get the care they need, when they need it—and ultimately help improve patient outcomes at scale.”
    At many of its CTC facilities, Acadia has used Uber Health for the past few years to provide transportation for patients.
  • The Uber Health platform allows Acadia to deliver care early in the patient’s recovery cycle.

Winners Named in IDC Government Insights' Seventh Annual Smart Cities North America Awards

Retrieved on: 
Wednesday, March 27, 2024
Urban Planning, Technology, Law Enforcement, Emergency Services, Professional Services, Public Policy, Government, Science, Data Analytics, Public Transport, Construction & Property, Transport, Research, Business, Sustainability, Environment, Social Services, Data Management, Consulting, EV, Connected, Municipal wireless network, Equipment, Public health, Coral Gables, Florida, Raleigh Convention Center, IDC, Americans, Digital twin, Trust, Build automation, Social services, Ecosystem, Future, Public sector, Addiction, Urban planning, Smart city, Inspection

IDC Government Insights today named the winners in the seventh annual Smart Cities North America Awards (SCNAA).

Key Points: 
  • IDC Government Insights today named the winners in the seventh annual Smart Cities North America Awards (SCNAA).
  • The awards were designed to recognize the progress North American states and municipalities have made in executing Smart Cities projects, as well as providing a forum for sharing best practices to help accelerate Smart City development in the region.
  • Winners will be honored at Smart Cities Connect being held May 7–10, 2024, at the Raleigh Convention Center in Raleigh, NC.
  • "We are thrilled to witness the continued dedication by government and education officials and technology partners to develop smart city initiatives for smart, sustainable outcomes."

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, Depression, Conference, American Chemical Society, Patent, Acceleration, Partnership, HERG, Patient, CNS, Journal, Anxiety, IND, Chemical substance, Addiction, Safety, Therapy, Arthropathy, Medicinal chemistry, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.
  • “The fourth quarter of 2023 and early 2024 was a significant period for Enveric, highlighted by the selection of EB-003 as our lead development candidate.
  • Continued to strengthen our intellectual property portfolio, receiving ten patent issuances from the United States Patent and Trademark Office.
  • The gross proceeds to the Company from the two warrant exercises totaled approximately $4.5 million.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Mental Health, Chemicals, Plastics, Manufacturing, Other Health, Depression, Cannabinoid, Rheumatoid arthritis, Patient, Anxiety, IND, Addiction, Pathology, Therapy, Osteoarthritis, Arthropathy, Steroid, Pharmaceutical industry

The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.

Key Points: 
  • The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.
  • Royalty rates could range from 2.5% up to 10% on future sales, depending on meeting certain sales criteria.
  • Together, through the out-licensing of the two assets and meeting various development and sales milestones, Enveric could potentially receive milestone payments that total up to approximately $82 million.
  • “We look forward to working with our partner, and we are confident in their leadership and capabilities to continue the development of these compounds for both pharmaceutical and non-pharmaceutical applications to advance joint disease treatment options for patients.